SCHEMBL2830668

SCHEMBL2830668

C=CCOC(=O)c1c(F)cccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.58
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
THRB P10828 1/20 0.48
KDM4E B2RXH2 1/20 0.46
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
RHOA P61586 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SNCA P37840 1/20 0.42
MAPT P10636 2/20 0.42
ELANE P08246 1/20 0.42
NPC1 O15118 1/20 0.42
S1PR4 O95977 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
XBP1 P17861 1/20 0.42
S1PR1 P21453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15867225 0.88 CYP3A4 (0.49) CYP3A4KMT2AALDH1A1TSHRHSD17B10
SCHEMBL7573253 0.84 CYP3A4 (0.51) CYP3A4KMT2AALDH1A1TSHRHSD17B10
SCHEMBL2835126 0.83 KMT2A (0.50) CYP3A4KMT2AALDH1A1THRBKDM4E
SCHEMBL2831985 0.82 CYP3A4 (0.49) CYP3A4KMT2AALDH1A1TSHRHSD17B10
SCHEMBL1456587 0.81 CYP3A4 (0.77) CYP3A4KMT2AALDH1A1TSHRHSD17B10
SCHEMBL2833609 0.80 KMT2A (0.48) CYP3A4KMT2AALDH1A1THRBKDM4E
SCHEMBL343095 0.80 CYP3A4 (0.76) CYP3A4KMT2AALDH1A1TSHRHSD17B10
SCHEMBL2834918 0.79 CES2 (0.50) KMT2ATHRBKDM4ECES2CES1
SCHEMBL2834974 0.79 KMT2A (0.50) KMT2AALDH1A1THRBKDM4ECES2
SCHEMBL2834462 0.79 MMP1 (0.54) KMT2AALDH1A1THRBKDM4ECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 CYP3A4 2090/4885KMT2A 1023/4885ALDH1A1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.